PUBLISHER: TechNavio | PRODUCT CODE: 1299620
PUBLISHER: TechNavio | PRODUCT CODE: 1299620
The non-small cell lung cancer drugs market is forecasted to grow by USD 15936.89 mn during 2022-2027, accelerating at a CAGR of 9.25% during the forecast period. The report on the non-small cell lung cancer drugs market provides a holistic analysis, market size, and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence and incidence of non-small cell lung cancer, the strong drug pipeline and recent drug approvals, and the availability of patient assistance programs.
Technavio's non-small cell lung cancer drugs market is segmented as below:
By Type
By Product
By Geographical Landscape
This study identifies the introduction and approval of combination therapies as one of the prime reasons driving the non-small cell lung cancer drugs market growth during the next few years. Also, an increase in strategic alliances to develop non-small cell lung cancer drugs and the use of predictive biomarkers for the development of cost-effective therapies will lead to sizable demand in the market.
The report on the non-small cell lung cancer drugs market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading non-small cell lung cancer drugs market vendors that include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., PharmaMar SA, Regeneron Pharmaceuticals Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd.. Also, the non-small cell lung cancer drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: